Clinical Trials /

Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

NCT04676477

Description:

This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety. The primary objectives: Dose Escalation: To assess the safety and tolerability of patritumab deruxtecan (U3-1402) and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 19 deletion or L858R mutation with tumor progression after treatment with osimertinib, and to determine the recommended combination dose (RCD). Second-Line Dose Expansion Arm 1 and Arm 1b: To assess the preliminary antitumor activity of patritumab deruxtecan and osimertinib in subjects with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation with tumor progression after treatment with osimertinib. Note: One or both of the study arms may open with one or two distinct dosing schedules. Second-Line Dose Expansion Arm 2: To assess the preliminary antitumor activity of patritumab deruxtecan monotherapy in subjects with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation with tumor progression after treatment with osimertinib. First-Line Dose Expansion: To assess the safety and tolerability of patritumab deruxtecan and osimertinib in subjects with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation without prior systemic treatment for locally advanced or metastatic disease.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Not yet recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
  • Official Title: A Phase 1 Open-Label Study of Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial IDs

  • ORG STUDY ID: U31402-A-U103
  • SECONDARY ID: 2020-003064-87
  • NCT ID: NCT04676477

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)

Interventions

DrugSynonymsArms
Patritumab deruxtecanU3-1402, HER3-DXdDose Escalation: Patritumab deruxtecan + osimertinib
Patritumab deruxtecanU3-1402, HER3-DXdSecond-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)
OsimertinibDose Escalation: Patritumab deruxtecan + osimertinib
OsimertinibSecond-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)
Patritumab deruxtecanU3-1402, HER3-DXdSecond-line Dose Expansion: Patritumab deruxtecan
Patritumab deruxtecanU3-1402, HER3-DXdFirst-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)
OsimertinibFirst-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)

Purpose

This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety. The primary objectives: Dose Escalation: To assess the safety and tolerability of patritumab deruxtecan (U3-1402) and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 19 deletion or L858R mutation with tumor progression after treatment with osimertinib, and to determine the recommended combination dose (RCD). Second-Line Dose Expansion Arm 1 and Arm 1b: To assess the preliminary antitumor activity of patritumab deruxtecan and osimertinib in subjects with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation with tumor progression after treatment with osimertinib. Note: One or both of the study arms may open with one or two distinct dosing schedules. Second-Line Dose Expansion Arm 2: To assess the preliminary antitumor activity of patritumab deruxtecan monotherapy in subjects with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation with tumor progression after treatment with osimertinib. First-Line Dose Expansion: To assess the safety and tolerability of patritumab deruxtecan and osimertinib in subjects with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation without prior systemic treatment for locally advanced or metastatic disease.

Detailed Description

      Dose Escalation:

      Population includes subjects with locally advanced or metastatic NSCLC with an EGFR exon 19
      deletion or L858R mutation with tumor progression after treatment with osimertinib. The
      starting combination dose regimen is patritumab deruxtecan 3.2 mg/kg IV every 21 days (Q3W)
      and osimertinib 80 mg orally (PO) once daily. At least 3 to 6 subjects will be enrolled in
      each cohort.

      Dose Expansion: Two subject populations will be evaluated in the Dose Expansion Part:

        -  Second-Line: Subjects with locally advanced or metastatic NSCLC with an EGFR exon 19
           deletion or L858R mutation with tumor progression after treatment with osimertinib

        -  First-Line: Subjects with locally advanced or metastatic NSCLC with an EGFR exon 19
           deletion or L858R mutation, and without prior systemic therapy for advanced or
           metastatic disease. Note: The first line expansion will only be initiated if the RCD
           includes osimertinib 80 mg PO once daily.
    

Trial Arms

NameTypeDescriptionInterventions
Dose Escalation: Patritumab deruxtecan + osimertinibExperimentalParticipants in the Dose Escalation phase will receive patritumab deruxtecan IV Q3W + osimertinib PO once daily. The dose of patritumab deruxtecan in the first cohort will be 3.2 mg/kg Q3W. The dose of osimertinib in the first cohort will be 80 mg PO once daily.
  • Patritumab deruxtecan
  • Osimertinib
Second-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)ExperimentalParticipants in the Second-line Dose Expansion phase will be randomized to receive patritumab deruxtecan + osimertinib at the RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
  • Patritumab deruxtecan
  • Osimertinib
Second-line Dose Expansion: Patritumab deruxtecanExperimentalParticipants in the Second-line Dose Expansion phase will be randomized to receive patritumab deruxtecan 5.6 mg/kg IV Q3W
  • Patritumab deruxtecan
First-line Dose Expansion: Patritumab deruxtecan + osimertinib (RCD)ExperimentalIf the RCD includes an osimertinib dose of 80 mg PO once daily, then participants will receive treatment with patritumab deruxtecan and osimertinib at the RCD or, if relevant, at one of the provisional RCDs once established in dose escalation
  • Patritumab deruxtecan
  • Osimertinib

Eligibility Criteria

        Inclusion Criteria:

        Inclusion Criteria Specific to Dose Escalation and Second-Line Dose Expansion:

          -  Documentation of EGFR exon 19 deletion or L858R mutation detected from tumor tissue

          -  Must have received osimertinib for locally advanced or metastatic disease at a dose of
             80 mg once daily (QD) for at least 6 weeks and must not miss more than two doses
             during the 2 weeks prior to the first day of study treatment (Cycle 1, Day 1)

          -  Must not have received any other prior systemic cancer therapies in the locally
             advanced/metastatic setting

          -  Has documentation of radiological disease progression following first-line treatment
             with osimertinib in the locally advanced or metastatic setting

        Inclusion Criteria Specific to First-line Dose Expansion:

          -  The tumor tissue harbors one of the 2 common EGFR mutations occurring in NSCLC known
             to be associated with EGFR-TKI sensitivity (exon 19 deletion or L858R) as assessed by
             Clinical Laboratory Improvement Amendments (CLIA)-certified (United States [US]
             sites), accredited (outside of the US), local laboratory or central laboratory. Only
             tissue-based testing will be accepted.

          -  Participants must have previously untreated locally advanced or metastatic NSCLC and
             must be eligible to receive first-line treatment with osimertinib, according to the
             judgment of the investigator. Prior adjuvant or neo-adjuvant therapy (chemotherapy,
             radiotherapy, investigational agents; except with osimertinib) is permitted.

        All Participants:

        Participants must meet all criteria to be eligible for inclusion in this study:

          -  Histologically or cytologically documented locally advanced or metastatic NSCLC not
             amenable to curative surgery or radiation.

          -  At least 1 measurable lesion as assessed by Investigator as per Response Evaluation
             Criteria in Solid Tumors (RECIST v1.1)

          -  Willing to provide required tumor tissue of sufficient quantity (as defined in the
             laboratory manual) and contain adequate tumor tissue content (as confirmed by
             hematoxylin and eosin (H&E) staining at central laboratory). Required tumor tissue can
             be provided as either:

               -  Pre-treatment tumor biopsy from at least 1 lesion not previously irradiated and
                  amenable to core biopsy OR

               -  Archival tissue collected from a biopsy performed within 3 months prior to
                  signing of the tissue consent and since progression while on the most recent
                  cancer therapy regimen.

               -  On-study tumor biopsies are required for the first 15 participants in Dose
                  Escalation.

          -  Has adequate bone marrow reserve and organ function based on local laboratory data
             within 14 days prior to Cycle 1, Day 1:

               -  Platelet count: ≥100 000/mm^3 or ≥100 × 10^9/L (platelet transfusions are not
                  allowed up to 14 days prior to Cycle 1, Day 1 to meet eligibility)

               -  Hemoglobin: ≥9.0 g/dL (transfusion and/or growth factor support is allowed)

               -  Absolute neutrophil count ; 1500/mm^3 or ≥1.5 × 10^9/L

               -  Serum creatinine (SCr) OR creatinine clearance (CrCl): SCr ≤1.5 × ULN, OR CrCl
                  ≥30 mL/min as calculated using the Cockcroft-Gault equation or measured CrCl;
                  confirmation of CrCl is only required when creatinine is >1.5 × ULN

          -  Aspartate aminotransferase/ alanine aminotransferase: ≤3 × ULN (if liver metastases
             are present, ≤5 × ULN)

          -  Total bilirubin: ≤1.5 × ULN if no liver metastases (<3 × ULN in the presence of
             documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver metastases)

          -  Serum albumin ; ≥2.5 g/dL

          -  Prothrombin time (PT) or PT-international normalized ratio (INR) and Activated partial
             thromboplastin time (aPTT) / Partial thromboplastin time (PTT): ≤1.5 × ULN, except for
             subjects on coumarin-derivative anticoagulants or other similar anticoagulant therapy,
             who must have PT-INR within therapeutic range as deemed appropriate by the
             Investigator.

        Exclusion Criteria:

          -  Any previous histologic or cytologic evidence of small cell OR combined small
             cell/non-small cell disease in the archival tumor tissue or pretreatment tumor biopsy.

          -  Any history of interstitial lung disease (including pulmonary fibrosis or radiation
             pneumonitis), has current interstitial lung disease (ILD), or is suspected to have
             such disease by imaging during screening.

          -  Clinically severe pulmonary compromise (based on Investigator's assessment) resulting
             from intercurrent pulmonary illnesses including, but not limited to:

               -  Any underlying pulmonary disorder (eg, pulmonary emboli within three months of
                  the study enrollment, severe asthma, severe chronic obstructive pulmonary
                  disease, restrictive lung disease, pleural effusion);

               -  Any autoimmune, connective tissue or inflammatory disorders with pulmonary
                  involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis); OR prior
                  pneumonectomy.

          -  Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent
             or any form of immunosuppressive therapy prior to Cycle 1, Day 1. Participants who
             require use of bronchodilators, inhaled steroids, or local steroid injections may be
             included in the study.

          -  Evidence of any leptomeningeal disease.

          -  Evidence of clinically active spinal cord compression or brain metastases, defined as
             untreated and symptomatic, or requiring therapy with corticosteroids or
             anticonvulsants to control associated symptoms. Participants with clinically inactive
             or treated brain metastases who are asymptomatic (ie, without neurologic signs or
             symptoms and do not require treatment with corticosteroids or anticonvulsants) may be
             included in the study.

          -  Inadequate washout period prior to Cycle 1, Day 1, defined as:

               -  Whole brain radiation therapy <14 days or stereotactic brain radiation therapy <7
                  days;

               -  Any systemic anticancer (excluding osimertinib in all Dose Escalation Cohorts and
                  in Second-Line Dose Expansion [Arms 1, 2, and 1b]), including investigational
                  agents, <14 days or 5 half-lives, whichever is longer

               -  Immune checkpoint inhibitor therapy <5 half-lives

               -  Major surgery (excluding placement of vascular access) <4 weeks

               -  Radiotherapy treatment to more than 30% of the bone marrow or with a wide field
                  of radiation < 28 days or palliative radiation therapy <14 days

               -  Chloroquine or hydroxychloroquine ≤14 days

               -  Medications or herbal supplemented known to be strong inducers of cytochrome P450
                  (CYP) 3A4 <21 days.

          -  Has unresolved toxicities from previous anticancer therapy, defined as toxicities
             (other than alopecia) not yet resolved to National Cancer Institute Common Terminology
             Criteria for Adverse Events (NCI-CTCAE) version 5.0, Grade ≤1 or baseline. Subjects
             with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator
             after consultation with the Sponsor Medical Monitor or designee.

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow osimertinib, or previous significant bowel resection that would preclude
             adequate absorption of osimertinib.

          -  Has any primary malignancy other than locally advanced or metastatic NSCLC within 3
             years prior to Cycle 1, Day 1, except adequately resected non-melanoma skin cancer,
             curatively treated in situ disease, or other solid tumors curatively treated.

          -  Uncontrolled or significant cardiovascular disease prior to Cycle 1, Day 1, including:

               -  Mean corrected QT interval using Fridericia's formula (QTcF) prolongation
                  interval of >470 ms for females and >450 ms for males in 3 successive screening
                  measurements

               -  Left ventricular ejection fraction (LVEF) <50% by either echocardiogram (ECHO) or
                  multigated acquisition (MUGA) scan

               -  Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic
                  blood pressure >110 mmHg)

               -  Myocardial infarction within 6 months

               -  New York Heart Association (NYHA) Classes 2 to 4 congestive heart failure within
                  28 days

               -  Uncontrolled angina pectoris within 6 months

               -  Has cardiac arrhythmia requiring antiarrhythmic treatment

               -  Complete left or right bundle branch block within 6 months

               -  History of second- or third-degree heart block or PR interval >250 ms within 6
                  months

               -  History of clinically relevant ventricular arrhythmias, such as ventricular
                  tachycardia, ventricular fibrillation, or Torsade de Pointes

               -  Has any factors that increase the risk of corrected QT (QTc) prolongation or risk
                  of arrhythmic events, such as heart failure, hypokalemia, congenital long QT
                  syndrome, family history of long QT syndrome, or unexplained sudden death under
                  40 years of age in first-degree relatives, or any concomitant medication known to
                  prolong the QT interval

          -  Has clinically significant corneal disease

          -  Any evidence of severe or uncontrolled diseases including active bleeding diatheses,
             active infection, psychiatric illness/social situations, geographical factors,
             substance abuse, or other factors which in the Investigator's opinion makes it
             undesirable for the subject to participate in the study or which would jeopardize
             compliance with the protocol. Screening for chronic conditions is not required.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Dose Escalation: Incidence of Dose-limiting Toxicities (DLT), Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)
Time Frame:From signing of informed consent form up to 40 days (+7 days) after the last dose of study drugs, up to approximately 9 months
Safety Issue:
Description:A DLT is defined as any TEAE not attributable to disease or disease-related processes that occurs during the DLT evaluation period and is ≥Grade 3, with exceptions as defined in the protocol. A TEAE is defined as an adverse event (AE) with a start or worsening date during the on-treatment period. A serious AE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event, or may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes noted. AESIs will also be assessed. AEs will be coded using MedDRA and graded using NCI-CTCAE v5.0.

Secondary Outcome Measures

Measure:Dose Escalation and First-line Dose Expansion: Objective Response Rate (ORR)
Time Frame:From start of treatment until date of disease progression or other reason for discontinuation (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 9 months (Dose Escalation) and 18 months (Dose Expansion)
Safety Issue:
Description:ORR is defined as the proportion of participants who achieved a best overall response of confirmed CR or confirmed PR as assessed by BICR and Investigator per RECIST v1.1.
Measure:Second-line Dose Expansion: Objective Response Rate (ORR)
Time Frame:From start of study treatment until the date of documented disease progression or other protocol-defined reason for discontinuation from the study (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 18 months
Safety Issue:
Description:ORR is defined as the proportion of participants who achieved a best overall response of confirmed CR or PR as assessed by Investigator per RECIST v1.1.
Measure:Dose Escalation, Second-line Dose Expansion, and First-Line Dose Expansion: Duration of Response (DoR)
Time Frame:From start of treatment until date of disease progression or other reason for discontinuation (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 9 months (Dose Escalation) and 18 months (Dose Expansion)
Safety Issue:
Description:DOR is defined as the time from the date of the first documentation of response (confirmed CR or confirmed PR) to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. DoR as assessed by BICR and Investigator per RECIST v1.1
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Disease Control Rate (DCR)
Time Frame:From start of treatment until date of disease progression or other reason for discontinuation (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 9 months (Dose Escalation) and 18 months (Dose Expansion)
Safety Issue:
Description:DCR is defined as the proportion of participants who achieved a best overall response of confirmed CR, confirmed PR, or stable disease (SD) as assessed by BICR and by Investigator per RECIST v1.1.
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Time to Response (TTR)
Time Frame:From start of treatment until date of disease progression or other reason for discontinuation (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 9 months (Dose Escalation) and 18 months (Dose Expansion)
Safety Issue:
Description:TTR is defined as the time from the start of study treatment to the date of the first documentation of response (confirmed CR or confirmed PR) in responding participants as assessed by BICR and by Investigator per RECIST v1.1.
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Progression-free Survival (PFS)
Time Frame:From start of treatment until date of disease progression or other reason for discontinuation (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 9 months (Dose Escalation) and 18 months (Dose Expansion)
Safety Issue:
Description:PFS is defined as the time from the start of study treatment to the date of the first documentation of objective PD as assessed by BICR and by Investigator per RECIST v1.1. or death due to any cause, whichever occurs first
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Overall Survival (OS)
Time Frame:From start of treatment until date of disease progression or other reason for discontinuation (e.g, withdrawal of consent, lost to follow-up), whichever occurs first, up to approximately 9 months (Dose Escalation) and 18 months (Dose Expansion)
Safety Issue:
Description:OS is defined as the time from the start of study treatment to the date of death due to any cause
Measure:Second-line Dose Expansion: Incidence of Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI)
Time Frame:From signing of informed consent form up to 40 (+7 days) days after the last dose of study drugs, up to approximately 18 months
Safety Issue:
Description:A TEAE is defined as an adverse event (AE) with a start or worsening date during the on-treatment period. A serious AE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event, or may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes noted. AESIs will also be assessed. Adverse events will be coded using MedDRA and will be graded using NCI-CTCAE v5.0.
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Proportion of Participants Who Have Treatment-emergent ADA
Time Frame:From the start of study treatment until the end of treatment or study discontinuation (whichever occurs first), up to approximately 9 months (Dose Escalation) and 18 months (Dose Expansion)
Safety Issue:
Description:The immunogenicity of patritumab deruxtecan will be assessed.
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Pharmacokinetic Parameter Maximum Concentration (Cmax)
Time Frame:Patritumab deruxtecan: Cycles 1 and 3, Day 1 pre- and postdose, 4 hours (h), Days 8 and 15; Cycle 2, Day 1 pre- and postdose; Cycles 4, 6, 8, Day 1 pre- and postdose; Osimertinib: Cycles 1, 2, and 3, Day 1 pre- and postdose, 4 h (each cycle is 21 days)
Safety Issue:
Description:Cmax will be assessed for patritumab deruxtecan, total anti-HER3 antibody, MAAA-1181a, osimertinib (except for Second-line Dose Expansion Arm 2), and AZ5104 (active metabolite of osimertinib; except for Second-line Dose Expansion Arm 2).
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Time Frame:Patritumab deruxtecan: Cycles 1 and 3, Day 1 pre- and postdose, 4 hours (h), Days 8 and 15; Cycle 2, Day 1 pre- and postdose; Cycles 4, 6, 8, Day 1 pre- and postdose; Osimertinib: Cycles 1, 2, and 3, Day 1 pre- and postdose, 4 h (each cycle is 21 days)
Safety Issue:
Description:Tmax will be assessed for patritumab deruxtecan, total anti-HER3 antibody, MAAA-1181a, osimertinib (except for Second-line Dose Expansion Arm 2), and AZ5104 (active metabolite of osimertinib; except for Second-line Dose Expansion Arm 2).
Measure:Dose Escalation, Second-line Dose Expansion, and First-line Dose Expansion: Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC)
Time Frame:Patritumab deruxtecan: Cycles 1 and 3, Day 1 pre- and postdose, 4 hours (h), Days 8 and 15; Cycle 2, Day 1 pre- and postdose; Cycles 4, 6, 8, Day 1 pre- and postdose; Osimertinib: Cycles 1, 2, and 3, Day 1 pre- and postdose, 4 h (each cycle is 21 days)
Safety Issue:
Description:AUC up to the last quantifiable time (AUClast) and AUC during dosing interval (AUCtau) will be assessed for patritumab deruxtecan, total anti-HER3 antibody, MAAA-1181a, osimertinib (except for Second-line Dose Expansion Arm 2), and AZ5104 (active metabolite of osimertinib; except for Second-line Dose Expansion Arm 2).

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Daiichi Sankyo, Inc.

Trial Keywords

  • Advanced Non-small Cell Lung Cancer
  • Inoperable Non-small Cell Lung Cancer
  • Patritumab Deruxtecan (U3-1402)
  • Unresectable
  • Epidermal growth factor receptor
  • Metastatic
  • EGFR
  • Osimertinib
  • HER3

Last Updated

December 21, 2020